Clerio Vision
Clerio Vision is a development-stage medical device company commercializing LIRIC, a femtosecond laser platform that writes optical prescriptions directly into contact lenses, intraocular lenses, and corneal tissue. It targets presbyopia, pediatric myopia, post-cataract IOL adjustment, and refractive surgery markets with investigational products.
- Company typePrivate
- Founded2003
- HeadquartersRochester, United States
- Headcount11–50
- GTM typeB2B
- OfferingHardware or Manufacturing
What Clerio Vision does
Clerio Vision is a development-stage medical device company developing a proprietary platform called LIRIC (Laser Induced Refractive Index Change), which uses ultra-short femtosecond laser pulses to write optical prescriptions directly into lens materials or corneal tissue without removing any material. The company's technology, derived from 2018 Nobel Prize-winning research at the University of Rochester's Center for Visual Sciences, enables computer-generated diffractive optical patterns to be inscribed at the molecular level into hydrogels, contact lenses, and intraocular lenses. Clerio is advancing four investigational product lines targeting distinct ophthalmic segments: multifocal soft contact lenses for presbyopia, therapeutic contact lenses for myopia control in children, a non-invasive post-implant intraocular lens adjustment procedure, and an incisionless corneal refractive correction procedure. The intellectual property estate spans more than 90 patents across 30+ patent families.
The company's business model is currently pre-commercial. All products are investigational devices that have not received FDA marketing approval or clearance and are not commercially available in the United States. Future revenue is expected to derive from two complementary streams: hardware sales of LIRIC-enabled contact lenses (presbyopia and myopia control), and professional services revenue from in-office LIRIC procedures for post-cataract IOL optimization and refractive correction. The company targets four large ophthalmic markets — $2.5B global presbyopia, the growing pediatric myopia epidemic projected to affect 50% of the world by 2050, the ~30% of cataract patients with residual refractive error post-surgery, and the refractive surgery market — through a clinical-research and physician-channel go-to-market motion. Clerio is conducting first-in-human trials and engaging clinical research sites in the US and Europe, with scientific conference presence (ARVO, Wavefront Congress, VPO, International Myopia Symposia) as the primary awareness channel. The company has raised approximately $80M from venture investors including Safar Partners, Hegemon Capital, Topmark Partners, Armory Square Ventures, ATMA Capital, and Proxima Ventures, supplemented by NSF STTR Phase I and Phase II grants. Manufacturing is conducted in-house at a Henrietta, NY facility following the 2019 acquisition of Hydrogel Vision.
Clerio Vision firmographics
Firmographics- Name
- Clerio Vision
- Legal name
- Clerio Vision, Inc.
- Website
- https://cleriovision.com
- Company type
- Private
- Founded year
- 2003
- Operating status
- Operating
- Headcount range
- 11–50 employees
- Short description
- Clerio Vision is a development-stage medical device company commercializing LIRIC, a femtosecond laser platform that writes optical prescriptions directly into contact lenses, intraocular lenses, and corneal tissue. It targets presbyopia, pediatric myopia, post-cataract IOL adjustment, and refractive surgery markets with investigational products.
- Ownership category
- akta.pro rank
Clerio Vision industry classification
Industry- Product category
- Ophthalmic Medical Devices
- NAICS
- Ophthalmic Goods Manufacturing (339115)
- SIC
- Ophthalmic Goods (3851), Surgical & Medical Instruments & Apparatus (3841)
- akta.pro primary industry
- Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions) (HLAHAJAE)
- akta.pro secondary industries
- Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics) (HLAHAJAH), Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance) (HLAHAJAG), Contact Lens Specialty & Myopia Control (HLAKAKAK), Cornea, External Disease & Refractive Surgery (LASIK/PRK) (HLAKAKAF)
Keywords
Where Clerio Vision is headquartered
LocationHeadquarters
- HQ city
- Rochester
- HQ country
- United States
- HQ region
- North America
Offices2 records
Markets served
Clerio Vision business model
Business model- GTM type
- B2B
- Offering type
- Hardware or Manufacturing
- Cost components
- Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
Revenue model
- Contact Lenses (Presbyopia): Next-generation multifocal soft contact lenses for aging eyes. Development stage - not yet commercialized.
- Myopia Control Lenses: Therapeutic soft contact lenses designed to slow myopia progression in children. Development stage - not yet commercialized.
- Intraocular Lens (IOL) Optimization: Post-surgical optimization of implanted IOLs using LIRIC to write corrective optics. Non-invasive in-office procedure.
- Laser Vision Correction: Incisionless corneal refractive correction procedure. Next revolution in refractive surgery.
Go-to-market motion3 records
Distribution channels1 record
Marketing channels7 records
Clerio Vision product offering
Product offeringCore offering
Clerio Vision is a development-stage medical device company commercializing its proprietary LIRIC (Laser Induced Refractive Index Change) femtosecond laser platform. The platform writes optical prescriptions directly into soft contact lens materials, intraocular lenses, and corneal tissue without removing material, enabling non-invasive vision correction products across four ophthalmic segments: presbyopia contact lenses, pediatric myopia control lenses, post-cataract IOL optimization, and incisionless laser vision correction.
Product overview
Clerio Vision offers the LIRIC (Laser-Induced Refractive Index Change) technology platform that enables non-invasive vision correction across multiple product categories. The platform uses femtosecond laser technology to write optical prescriptions directly into contact lens materials, intraocular lenses, and corneal tissue without material removal. Product portfolio includes: LIRIC multifocal contact lenses for presbyopia, LIRIC myopia control therapeutic lenses for children, LIRIC-enabled intraocular lenses (IOL) for post-cataract adjustment, and LIRIC laser corneal refractive correction. All products share the same underlying LIRIC technology platform, allowing the company to address presbyopia, myopia control, cataract surgery optimization, and laser vision correction markets.
Differentiator
Problem solved
Functional benefit
Brands
- LIRIC: Laser Induced Refractive Index Change - proprietary femtosecond laser technology platform that modifies the refractive index of lens materials to create advanced optical designs for vision correction.
Products and services
- LIRIC Multifocal Contact Lenses (Presbyopia) Advanced multifocal soft contact lenses for patients with presbyopia that embed computer-generated micro-patterns inside the lens material to deliver superior visual quality, reduced halos and glare, and sharp vision at near, intermediate, and far distances.
- LIRIC Myopia Control Lenses Therapeutic soft contact lenses for pediatric use that use LIRIC-inscribed tailored defocus patterns to induce stronger myopia-slowing optical signals while preserving comfort, intended to slow myopia progression in children.
- LIRIC Intraocular Lens (IOL) Post-Implant Adjustment Device and procedure that uses LIRIC to write corrective optics into intraocular lenses after implantation, enabling a non-invasive in-office upgrade from standard monofocal IOLs to multifocal performance to correct residual refractive error after cataract surgery.
- LIRIC Laser Vision Correction Incisionless corneal refractive correction procedure that alters the refractive index of the cornea without cutting, flap creation, tissue removal, or ablation, significantly reducing dry-eye risk and preserving corneal structural integrity compared to conventional LASIK.
Quantifiable outcome
- LIRIC enables production of diffractive phase profiles over 5.0 mm optical zone at four diffractive power levels, with 3.0 diopter design neutralizing eye's native LCA and 6.0 diopter design reversing its sign
- +2 more outcomes
Companies that use Clerio Vision
Customer profileSegments4 records
Ideal customer profiles1 record
Clerio Vision technology and API
TechnologyTechnology focussed Yes
API detail
- Has API
- No
- API docs
- API detail
Core technology
AI maturity
App detail
Feature6 records
Clerio Vision partnerships and signals
Strategic signalPartnerships
Four partnerships are on record, tiered core.
- University of Rochester - Center for Visual SciencecoreWorld leader in optics and visual science. Company was founded out of Nobel Prize-winning (2018) research at this institution. Ongoing collaboration includes co-authored research with researchers from the center.
- Aier Eye Hospital (China)coreMulti-national research collaboration partner in study examining retinal image quality in Chinese children, published in Journal of the Optical Society of America A.
- Wroclaw University of Science and Technology (Poland)coreInternational research collaboration partner in multi-national study on optical quality and anisotropy in children's eyes.
- University of Murcia (Spain)coreInternational research collaboration partner in multi-national study on optical quality and anisotropy in children's eyes.
Scale indicators5 records
Recent moves6 records
Expansion highlights5 records
Clerio Vision competitors and assessment
Company assessmentBroad incumbents
- CooperVision: One of the four global soft contact lens majors (Biofinity, Proclarity, MiSight for myopia control). Directly competes in the multifocal and myopia control categories Clerio is targeting, and serves as the most likely strategic acquirer given its specialty lens focus.
- Alcon: Global leader in contact lenses (Dailies, Precision, Air Optix) and a major IOL player (PanOptix, Vivity). Competes in all four of Clerio's target segments and has the manufacturing scale and clinician relationships to dominate or acquire next-generation optical technologies.
- Johnson & Johnson Vision: Acuvue franchise is the global #1 in soft contact lenses and J&J Vision is a top IOL manufacturer (TECNIS). Direct competitor across Clerio's contact lens and IOL applications, with vast clinical infrastructure and consumer brand power.
- Bausch + Lomb: Major contact lens (Biotrue, Ultra) and IOL (enVista, Trulign) manufacturer competing in both of Clerio's primary product lanes, with growing interest in myopia management.
- Carl Zeiss Meditec: Dominant supplier of excimer and femtosecond lasers for LASIK/SMILE refractive surgery and premium IOLs (CT LUCIA, AT ELANA). Direct competitor in the incisionless refractive correction lane and a natural strategic acquirer for LIRIC-enabled corneal applications.
Direct peers
- SightGlass Vision: CooperVision-owned company developing Diffusion Optics Technology (DOT) spectacle lenses for slowing pediatric myopia progression. Closest direct competitor in the myopia-control optical-signature space, validating that Clerio's peripheral-defocus thesis is commercially pursuable.
- STAAR Surgical: Specialty IOL company (ICL for refractive correction, Visian Toric ICL) competing in premium cataract and refractive surgery segments. Closely comparable to Clerio's IOL-adjustment and refractive correction business model.
- LENSAR: Femtosecond laser cataract surgery system maker competing in the premium cataract segment. Highly relevant for Clerio's post-implant IOL adjustment application, which would be deployed alongside cataract surgery laser platforms.
Others
- Johnson & Johnson Vision (TearScience/LipiFlow): J&J's ophthalmic surgical device franchise spans LASIK (iFS), SMILE-related equipment, and IOLs. Adjacent incumbent for refractive surgery and cataract applications and the most likely acquirer if Clerio seeks a strategic exit.
Emerging players
- Euclid Systems Corporation: Specialist in orthokeratology (Ortho-K) and myopia management with the Euclid Emerald lens. Competes with Clerio's myopia control contact lens in the pediatric ophthalmology channel and provides a benchmark for specialty myopia-control commercialization.
Market position
Strengths5 records
Weaknesses5 records
Competitive moat3 records
Key risks6 records
Key highlights6 records
Customer concentration
Clerio Vision social profiles
Digital presenceClerio Vision compliance and trust
Trust signalCompliance2 records
Clerio Vision financial estimates
Financial estimateRevenue estimate
Valuation estimate
Clerio Vision leadership team
Management profileNumber of profiles
Profiles14 records
Clerio Vision funding detail
Funding detailFunding overview
Funding rounds10 records
Investors11 records
Funding detail is available on the Subscription and Enterprise plan.Contact sales →
Clerio Vision M&A and investment
M&A and investmentM&A1 record
Investments
M&A and investment is available on the Subscription and Enterprise plan.Contact sales →
Frequently asked questions about Clerio Vision
What does Clerio Vision do?
Clerio Vision is a development-stage medical device company commercializing its proprietary LIRIC (Laser Induced Refractive Index Change) femtosecond laser platform. The platform writes optical prescriptions directly into soft contact lens materials, intraocular lenses, and corneal tissue without removing material, enabling non-invasive vision correction products across four ophthalmic segments: presbyopia contact lenses, pediatric myopia control lenses, post-cataract IOL optimization, and incisionless laser vision correction.
Is Clerio Vision a public or private company?
Clerio Vision is a private company. It is classified as venture growth investor backed and is currently operating.
When was Clerio Vision founded?
Clerio Vision was founded in 2003. It employs 11 to 50 people.
Where is Clerio Vision based?
Clerio Vision is headquartered in Rochester, United States, in the North America region.
How does Clerio Vision make money?
Four revenue lines are on record. Contact Lenses (Presbyopia) is the primary driver. The others are myopia Control Lenses, intraocular Lens (IOL) Optimization and laser Vision Correction.
Who are Clerio Vision's main competitors?
Broad incumbents on record are CooperVision, Alcon, Johnson & Johnson Vision, Bausch + Lomb and Carl Zeiss Meditec. Direct peers are SightGlass Vision, STAAR Surgical and LENSAR. Johnson & Johnson Vision (TearScience/LipiFlow) is listed as an others. Euclid Systems Corporation is listed as an emerging player.
Does Clerio Vision have an API?
No public API is recorded for Clerio Vision.
What industry is Clerio Vision in?
Clerio Vision's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAE, Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions), with a secondary code of HLAHAJAH, Cataract Surgery Systems & IOLs (Phaco Systems, IOLs, Intraoperative Aberrometry, Viscoelastics). Its NAICS code is 339115 and its SIC code is 3851.